Celcuity Inc Dossier
Qualitative Analysis
Business overview
Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (PAM) pathway. Originally focused on its proprietary CELsignia functional cell-signaling diagnostic platform, Celcuity shifted its primary focus to drug development after licensing gedatolisib from Pfizer in 2021. Gedatolisib's mechanism of action and pharmacokinetic properties are highly differentiated from other approved or investigational therapies that target individual nodes of the PAM pathway, positioning it as a potential best-in-class oncology therapeutic.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building out the commercial infrastructure, including senior leadership and field sales representatives, to prepare for the rapid commercial launch of gedatolisib in the United States following potential FDA approval.
Expected impact: Establishment of a commercial footprint targeting high-prescribing doctors in community and academic settings, addressing a multi-billion dollar market.
Expanding the clinical development of gedatolisib, including the VIKTORIA-2 Phase 3 trial for first-line HR+/HER2- advanced breast cancer and the development of a subcutaneous injection formulation.
Expected impact: Broadening the therapeutic utility, patient convenience, and patent exclusivity (extending U.S. exclusivity to 2042) of gedatolisib.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. Grants Celcuity exclusive worldwide rights to develop and commercialize gedatolisib, which is now Celcuity's lead therapeutic candidate.
Terms: $5 million cash and $5 million in common stock upfront; Pfizer is eligible for up to $330 million in development and sales-based milestones, plus tiered royalties on potential sales.